'''لږ-ګڼ ليپوپروټين''' يا '''لږ-ګڼ شهمي پروټين''' ''(په انګرېزي: Low-density lipoprotein يا په لنډه LDL)'' د ليپوپروټينو د پينځو سترو ډلو نه يوه ډله شهمي پروټين دي چې د غټې کچې نه تر وړې کچې په دې ترتيب اوډل کېږي، کايلومايکرون، خورا لږ-ګڼ ليپوپروټين/شهمي پروټين، منځنی-ګڼ ليپوپروټين/شهمي پروټين، لږ-ګڼ ليپوپروټين/شهمي پروټين، ډېر-ګڼ ليپوپروټين/شهمي پروټين. دا ليپوپروټينونه د ژونکو نه چاپېر اوبلن چاپېريال او د اوبو پر بنسټ د وینې بهير کې د غوړو د ګڼ شمېر ماليکولونو، چې په دغو کې [[کولېسټرول]] هم راځي، د لېږدېدو چارې برابروي. څېړنيزو زده کړو جوته کړې چې په لوړه کچه د بي-ډول لږ-ګڼ ليپوپروټينونه (اې-ډوله لږ-ګڼ ليپوپروټينو په خلاف) روغتيايي ستونزې او د زړه او رګونو ناروغيو ته وده ورکوي. دا ډول ليپوپروټينونه اکثراً د ''بد کولېسټرول'' په نامه هم پېژندل کېږي او د دغو په خلاف ډېر-ګڼ ليپوپروټينونه د ''ښه کولېسټېرول'' په نامه پېژندل کېږي.<ref>[http://www.americanheart.org/presenter.jhtml?identifier=180 LDL and HDL Cholesterol: What's Bad and What's Good?]</ref>

==د آزمېښتون آزموينې ==
په درملګريزو آزمېښتونو کې اکثرا د وينې اخيستنې وروسته په وينه کې د LDL-C کچې راپور وړاندې کېږي، دا هغه معيار دی چې د کولېسټرول لرونکو لږ-ګڼ ليپوپروټينو شمېر پرې څرګندېږی. په کلينيکي لحاظ، دا اندازه شوی شمېر ډېر ارزښت لري. د شمېرپوهنې له مخې د LDL-C د کچې شمېر د هغو لږ-ګڼ ليپوپروټينو د څومره والي په اټکل کېدو کې کارېږی چې روغ بدن د اتېروسکلېروسېز ناروغۍ په لور بيايي.  

د LDL نېغه مېچنه هم په آزمېښتون کې شونې ده او د پورته ياد شوي آزمېښت په پرتله په ځينو ځاينو کې موثره هم ده. خو دا آزمېښت د ډېر لګښت او په ځانګړو آزمېښتونونو کې د ترسره کېدنې په پار ډېر نه ترسره کېږي. په ۲۰۰۸ ز. کال کې [[امريکایی ډيابېټېز تنظيم|ADA]] او [[د زړه پوهنې امريکايي پوهنځی|ACC]] د [[هستوي مقناتيسي رېزونېنس|NMR]] په مرسته د LDL ماليکولونو نېغه مېچنه تصويب کړه چې په ځينو روابطو کې تر ټولو ښه او په ځینو وګړو کې د زړه او رګونو د رنځونو د وېرې په اټکلېدو کې کارېږي.<ref>John D. Brunzell, MD, FACP, Michael Davidson, MD, FACC, Curt D. Furberg, MD, PhD, Ronald B. Goldberg, MD, Barbara V. Howard, PhD, James H. Stein, MD, FACC, FACP and Joseph L. Witztum, MD Lipoprotein Management in Patients With Cardiometabolic Risk, J Am Coll Cardiol, 2008; 51:1512-1524. [http://content.onlinejacc.org/cgi/content/full/j.jacc.2008.02.034#BIB25]</ref>

==ژونکيميا==
===جوړښت===
Each native LDL particle contains a single [[apolipoprotein]] B-100 molecule ([[apolipoprotein B-100|Apo B-100]], a protein that has 4536 [[amino acid]] residues and a mass of 514 [[kDa]]), which circulates the fatty acids, keeping them soluble in the aqueous environment.{{Citation needed|reason=not common knowledge|date=January 2012}} In addition, LDL has a highly hydrophobic core consisting of polyunsaturated fatty acid known as ''linoleate'' and about 1500 esterified cholesterol molecules.{{Citation needed|reason=Unable to find anything that confirms this|date=January 2012}} This core is surrounded by a shell of phospholipids and unesterified cholesterol, as well as the single copy of Apo B-100. LDL particles are approximately 22&nbsp;nm (0.00000087&nbsp;in.) in diameter and have a mass of about 3 million [[atomic mass unit|daltons]], but since LDL particles contain a changing number of fatty acids, they actually have a distribution of mass and size.<ref>{{Cite journal|author=Segrest JP, Jones MK, De Loof H, Dashti N |title=Structure of apolipoprotein B-100 in low density lipoproteins |journal=Journal of Lipid Research |volume=42 |issue=9 |pages=1346–67 |year=2001 |month=September |pmid=11518754 |url=http://www.jlr.org/cgi/pmidlookup?view=long&pmid=11518754}}</ref> Determining the structure of LDL has been a tough task because of its heterogeneous structure. First structure of LDL at human body temperature in native condition has been recently found using cryo-electron microscopy and it has resolution of 16 Angstrom.<ref>{{Cite journal|author=Kumar V, Butcher SJ, Katrina O,Engelhardt P,Heikkonen J, Kaski K, Ala-Korpela M, Kovanen PT. |title=Three-Dimensional cryoEM Reconstruction of Native LDL Particles to 16Å Resolution at Physiological Body Temperature |journal=PLoS ONE |year=2011 |month=May|pmid=21573056 |url=http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0018841 |doi=10.1371/journal.pone.0018841 |pmc=3090388 |volume=6 |issue=5 |pages=e18841}}</ref>

===د LDL څېرمه ډولونو مخبېګلې===
LDL particles vary in size and density, and studies have shown that a pattern that has more small dense LDL particles, called ''Pattern B'', equates to a higher risk factor for [[coronary heart disease]] (CHD) than does a pattern with more of the larger and less dense LDL particles (''Pattern A'').  This is because the smaller particles are more easily able to penetrate the [[endothelium]]. ''Pattern I'', for ''intermediate'', indicates that most LDL particles are very close in size to the normal gaps in the endothelium (26&nbsp;nm). {{Citation needed|date=February 2011}}  According to one study, sizes 19.0 to 20.5&nbsp;nm were
designated as pattern B and LDL sizes 20.6–22&nbsp;nm were designated as pattern A.<ref>http://onlinelibrary.wiley.com/doi/10.1002/clc.4960280510/pdf</ref>

Some in the medical community have suggested the correspondence between Pattern B and CHD is stronger than the correspondence between the LDL number measured in the standard lipid profile test.  Tests to measure these LDL subtype patterns have been more expensive and not widely available, so the common lipid profile test is used more commonly. <ref>http://www.msnbc.msn.com/id/35058896/ns/health-heart_health/t/bad-cholesterol-its-not-what-you-think/#.T4Gkub_Owrg</ref>

There has also been noted a correspondence between higher triglyceride levels and higher levels of smaller, denser LDL particles and alternately lower triglyceride levels and higher levels of the larger, less dense LDL.<ref name="pmid12417832">{{Cite journal|author=Superko HR, Nejedly M, Garrett B |title=Small LDL and its clinical importance as a new CAD risk factor: a female case study |journal=Progress in Cardiovascular Nursing |volume=17 |issue=4 |pages=167–73 |year=2002 |pmid=12417832 |doi=10.1111/j.0889-7204.2002.01453.x}}</ref><ref name="Warnick"/>

With continued research, decreasing cost, greater availability and wider acceptance of other ''lipoprotein subclass analysis'' assay methods, including [[NMR spectroscopy]],<ref>{{Cite journal|author=Otvos J |title=Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy |journal=Clin Cardiol |volume=22 |issue=6 Suppl |pages=II21–7 |year=1999 |month=June |pmid=10376193 |doi= |url=}}</ref> research studies have continued to show a stronger correlation between human clinically obvious cardiovascular event and quantitatively measured particle concentrations.{{Citation needed|date=September 2011}}

===ژونکې منځ ته لېږدېدنه===
When a cell requires cholesterol, it synthesizes the necessary [[LDL receptors]], and inserts them into the plasma membrane. The LDL receptors diffuse freely until they associate with [[clathrin]]-[[Caveolae|coated pits]]. LDL particles in the blood stream bind to these extracellular LDL receptors. The clathrin-coated pits then form vesicles that are endocytosed into the cell.

After the clathrin coat is shed, the vesicles deliver the LDL and their receptors to early [[endosomes]], onto late endosomes to lysosomes. Here the cholesterol esters in the LDL are hydrolysed. The LDL receptors are recycled back to the plasma membrane.

== سرچينې ==
{{Reflist}}
